<DOC>
	<DOC>NCT01083264</DOC>
	<brief_summary>Influence of different application sites on the blood levels after administration of a fertility control patch</brief_summary>
	<brief_title>Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<criteria>Healthy female subjects Age 1845 years Body mass index (BMI) 1830kg/mÂ² At least 3 months since delivery, abortion, or lactation before the first screening examination Ability to understand and follow studyrelated instructions Willingness to accept the synchronizing cycle and to use nonhormonal methods of contraception after starting the synchronizing cycle and during the treatment periods Contraindications for use of combined (estrogen/progestin) contraceptives (e.g. history of venous/arterial disease, liver disorders, migraine) Skin diseases with suspected alteration of dermal resorption and /or increased risk for dermal intolerance Regular use of medicines other than contraceptives Smokers (at the age of 31 to 45 years) Clinically relevant findings (e.g. blood pressure, physical and gynecological examination, laboratory examination)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>